


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+5.90%
-0.19%
-1.55%
MESO
Mesoblast Limited
$18.84
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
MESO Price Performance
$19.5 (-3.38%)
$16.36 (+15.16%)
$13.12 (+43.60%)
$18.68 (+0.86%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MESO Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MESO Street Sentiment is extremely bullish and have positive views on the near-term outlook
MESO has High risk level
Risks Indicators

Beta greater than 1.0

Low volume

Average key support and resistance price levels
What is MESO current stock price?
What are MESO stock strengths?
What is MESO Risk Level?
What is MESO market cap and volume?
What is MESO current Stock IQ?
Should I buy MESO stock right now?
Is MESO a Strong Buy right now?
What does a 'Strong Buy' rating mean for MESO?
What does a 'Strong Sell' rating mean for MESO?
What factors influence MESO's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+5.90%
-0.19%
-1.55%
MESO
Mesoblast Limited
Current Price
$18.84
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

MESO Price Performance
$19.5 (-3.38%)
$16.36 (+15.16%)
$13.12 (+43.60%)
$18.68 (+0.86%)
MESO Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MESO Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MESO Street Sentiment is extremely bullish and have positive views on the near-term outlook
MESO has High risk level
Risks Indicators

Beta greater than 1.0

Low volume

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Dec 15, 2025
Upgrade
Buy
Jefferies
Nov 26, 2025
Upgrade
Buy
Jefferies
MESO Stock IQ
MESO Latest Analysis
FDA Signals Support For Mesoblasts Cell Therapy For Chronic Back Pain. On Sunday ) provided feedback received from the United States Food &. Drug Administration (FDA) on potential filing of a Biologics License Application (BLA) for its allogeneic cell therapy product rexlemestrocel-L for chronic .The update follows FDA’.s Type B meeting review of data from Mesoblast’.s first randomized controlled Phase 3 trial (MSB-DR003) on pain reduction and relationship to decreased use or elimin
Tue Jan 20, 2026
Mesoblast rises as Ryoncil sales climb 60% in December quarter.
Fri Jan 9, 2026
Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales. ) shares are trading higher on Friday after the company reported strong year‑over‑year growth in December quarter sales of its .Mesoblast stock is approaching key resistance levels. Ryoncil is the first mesenchymal stromal cell therapy ever approved by the FDA and it remains the only FDA‑approved treatment for children under 12 with steroid‑refractory acute graft‑versus‑host disease. The therapy is now moving into a crucial
Fri Jan 9, 2026
Mesoblast Surges As Flagship Product Ryoncil Delivers Strong Quarterly Sales Growth . (RTTNews) - Shares of Mesoblast Ltd (MESO) jumped more than 8% in after-hours trading on Thursday after the company reported continued strong quarterly growth in sales of its flagship product Ryoncil.
Fri Jan 9, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MESO Stock trends
MESO Stock performance
MESO Stock analysis
MESO investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.